- All
- Blog
- Congress
- Scientific resource
- Webinar
- Poster
- Scientific publication
- Press release
- Press coverage
- News

Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model
Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model

Service partnership agreement between Oncodesign and Galderma
Press Release: Multi-year service contract: design and discover new drug candidates in dermatology - Galderma.

Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice
Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice

Centre Georges François Leclerc Presents the Detailed Results of the First Two Stages of its Clinical Study in Lung Cancer at the EANM Congress
Presentation of detailed results from the first two stages of the clinical trial in lung cancer | 31st EANM1 | 2018.

Precision medicine: Cap Digital and Medicen Paris-Region team-up with Oncodesign, Servier and Intersystems on Hu-PreciMED
Hu-PreciMED project will gear French precision medicine industry towards discovering new diagnostic approaches & novel therapeutic treatments.

Oncodesign furthers its cooperation with Eisai, started 12 years ago
This services agreement aims to evaluate the anti-tumor efficacy of Eisai new compounds...

Oncodesign announces the results of the second stage of its clinical study in lung cancer
The results confirm the radiotracer’s potential as a companion biomarker for patientssuffering from non-small-cell lung cancer.



